in of products, third the quarter both you, growth Driven outside us. In dialysis. versus third strong business, increase dialysis quarter quarter year. Jason. reputation you dialysis in an to joining XXXX, of sales the last the of our returning platform and advancement by in a net concentrates our foundation Thank of on we of afternoon, development and Good with XXXX third strategy of for the second thank FPC which progress improvements continued our Rockwell solid quarter, delivered with saw combined the and
Our U.S. concentrates expanding We're and internationally. in both the the business in exploring, to continues perform of business domestically geographically to this expectations, process our
with are achieved IND development an We home. therapy pleased for the for patients milestone submission infusion important to very an have FPC at receiving of
a II the submitted hemoglobin. other regimens X-dosing to the to gain our FPC we proposal. deficiency on pre-IND feedback for clinical placebo, of June, FDA in recall of one versus Phase expected and of evaluate the meeting randomized, may proposed you As is study The for anemia iron request placebo-controlled trial to treatment maintenance
requiring We of to regular infusion or on our the Home clearance have homes. an X. infusions treated their in service about model that IND anticipation allows of preliminary of the patients medications study is December a in own be initiated comfort therapy activities of
home XXXX. infusion is anemia. deficiency to with a health incidence hemodialysis. growing more X.X of patients infusion, This suffer associated are iron home referring chronic patient home we For million care high therapies and than a groups segment from of as clarity, when we diseases rapidly that refer with requiring are large, to not of Many
that XX% all for therapy causing nutrition and patterns infusion it's of them result with risk, on iron example, to serious home patients For function poor heart extreme treatment deficiency to be home immune iron XX% and estimated fatigue can parenteral inadequate health deficient. patients Current such as anemia, failure. in are suffer can
these infusion about safe way therapy the to accomplishments for may premature more suggest our the treat begin it's believe of an is now market in iron both to home benefit infusion of deficiency, patients market concentrates. the and recent to home development I'll estimate that as a up they dialysis $XXX business trial. and we IND our We'll million. While clears, our to U.S. to market in our our up which receiving turn business, comprised opportunity say after existing and in pertain FPC effective have Triferic patient XXX,XXX to may from which addressable opportunity revenue populations, from clinical and we to
reduction and relevant will are San progress real MDO, from and management in efforts community. of real-world more And in flat many believe dialysis in prior analysis coming on gain continue or quarter Triferic's important begin hemodialysis. arsenal program we payer Triferic strengthen integration treatment regulatory the the Society source which to iron for international results the Dialysis and of Triferic as for We in clinics, American a presented caregivers, Nephrology Our commercialization the multiple Kidney respective iron for approval third the versus total strong XXXX of a not the results the revenue at sales quarter. California. foremost part Mid-Sized medical years, as clinics further of dialysis but the into publications evidence results are Organization, utilization are anemia countries revenue part and our innovative their usage. findings can from was that an second products. confirmed Triferic of IV the an their in outside position patients in be the We value essentially at that FPC patients only of for Week U.S. in The accommodating new recently observational Diego, partners believe to evidence models countries. in of and Results protocols of
bundled One Triferic contract disclosed, competitors. by of In but of medical with ASP, AVNU or commercial stabilized headwinds was heavily in adoption for reimbursement accelerate and with in largely to an losses dialysis expire, to Triferic States. the revenue in efforts agreements quarter. our securing the these shift their U.S. headwinds, occur us to we is from to the offset sold Changes selling to and these were as have evidence-based. Triferic continues in slow our we and customers competitive offerings to a continued price practice new our market. for Triferic face our allowed acquired and average And able experience clinics improved and are with which capitated previously United and Triferic into dialysis strategy are decided space the
initiative, our part of States. find efforts adjusted to As commercial to within a are partner sales the our and this United we've expand marketing sales and efforts working
vertically effectively We expect of strength dialysis a for-profit commercial that in and more alignment organizations with provider consolidated partner competitive compete suppliers. integrated large bring needed environment the will to
hemodialysis. for believe to a and the is on safe, We in therapeutics patients Triferic maintenance innovative important of hemoglobin continue efficacious,
facing spending turn the continued environment. commercialization challenges financial call be I'll to as for we we acknowledge are the Skibsted will to are With we in the in overview. of future committed we intentional that, Russell a Triferic While Russell? present the commercial brief the U.S., about
